Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PBS Biotech selects GCMS to market single-use bioreactors in Korea
PBS’ single-use bioreactors will be used for R&D and production by the Korean firms. PBS’ bioreactors, which employ a low shear Air Wheel mixing mechanism, are utilized to
PBS’ single-use bioreactors will be used for R&D and production by the Korean firms. PBS’ bioreactors, which employ a low shear Air Wheel mixing mechanism, are utilized to
Presently, the drug is being under investigation in a Phase II SHELTER study as a second-line treatment for advanced hepatocellular carcinoma and in SAPHIRE Phase II study, as
The funds are expected to be used for product development and for commercializing the company’s prebiotic products for the dietary supplement and health food markets. Prebiotics are non-digestible
PPD‘s net income was $45.42m, compared to $20.98m for the same period in the prior year. The company has posted operating income of $57.15m for the second quarter
As per the terms of the deal, Astellas is eligible to get an undisclosed upfront payment from Merck along with development, regulatory and sales milestone. Earlier, Cardiome Pharma
The granting of certificate follows a proper inspection conducted by the Belgian authorities in May 2011. With this certification, Ablynx is now eligible to conduct preclinical testing and
Under the agreement, CSL has got the rights for using a cell line for the cGMP production of an undisclosed antibody. The licensed cell line was generated by
Gilead Sciences‘ net income was $746.23m, compared to $712.06m for the same period in the prior year. The company’s income from operations was $1.02bn for the second quarter
Raintree Systems Version 10 is a 2011/2012 compliant and has been certified as a Complete EHR by ONC-ATCB, in accordance with the applicable certification criteria adopted by the
The US Food and Drug Administration has approved eltrombopag under the trade name Promacta as a treatment of chronic ITP who have had an insufficient response to corticosteroids,